Our Research

Advance Research

Conquering and curing brain tumors – once and for all.

From basic science to clinical trial designs, the National Brain Tumor Society partners with the world’s leaders in research, public policy, and clinical care to advance the understanding of brain tumors, expand the availability of new treatments, and drive the discovery of a cure. With targeted programs for both adult and pediatric brain tumors, as well as other strategic initiatives to improve access and approvals of newfound discoveries, we drive bold, innovative programs to ensure a brighter future.

Our funding strategy

 

Our Funding Strategy

Driven by the needs of this community, we have funded more than $38 million dollars of promising and innovative research for both adults and pediatric brain tumors.

Research funding opportunities

 

Funding Opportunities

Our innovative funding models are designed to support rigorous scientific investigation and drive progress toward treatments and the discovery of a cure.

From the Blog

  • August 6, 2019

    A Missing Link to Glioblastoma Growth?

    An enzyme that serves as a link between oncogenes and the lipids that make-up cells’ membranes may be an important new drug target to treat glioblastoma and other tumors Glioblastoma, like all cancers, develops and progress

    Read More

  • August 5, 2019

    NBTS Brain Tumor Clinical Trials Report – August 2019

    Brain tumor clinical trials open around the country all the time, and it can be hard for patients and care partners to keep track of new opportunities to consider participation in leading-edge clinical research. This report, generated by the

    Read More

  • August 1, 2019

    Phase III Brain Tumor Clinical Trials Open for Patient Enrollment – July 2019 Update

    Below is a list of phase III clinical trials that are currently open for primary brain tumor patients in the United States. A phase III clinical trial is traditionally the last, pivotal step in the evaluation of a potential new medi

    Read More

More from the blog